106 related articles for article (PubMed ID: 3130986)
1. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma.
Wilhelm O; Hafter R; Coppenrath E; Pflanz MA; Schmitt M; Babic R; Linke R; Gössner W; Graeff H
Cancer Res; 1988 Jun; 48(12):3507-14. PubMed ID: 3130986
[TBL] [Abstract][Full Text] [Related]
2. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants.
Menzin AW; Loret de Mola JR; Bilker WB; Wheeler JE; Rubin SC; Feinberg RF
Cancer; 1998 Jan; 82(1):152-8. PubMed ID: 9428492
[TBL] [Abstract][Full Text] [Related]
3. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
[TBL] [Abstract][Full Text] [Related]
4. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
6. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
[TBL] [Abstract][Full Text] [Related]
7. Production of fibronectin by peritoneal macrophages and concentration of fibronectin in peritoneal fluid from patients with or without endometriosis.
Kauma S; Clark MR; White C; Halme J
Obstet Gynecol; 1988 Jul; 72(1):13-8. PubMed ID: 3380502
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.
Nagy JA; Morgan ES; Herzberg KT; Manseau EJ; Dvorak AM; Dvorak HF
Cancer Res; 1995 Jan; 55(2):376-85. PubMed ID: 7529135
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators and inhibitors are transcribed during early macaque implantation.
Feng Q; Liu K; Liu YX; Byrne S; Ockleford CD
Placenta; 2001; 22(2-3):186-99. PubMed ID: 11170823
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer.
Hazelbag S; Gorter A; Kenter GG; van den Broek L; Fleuren G
Hum Pathol; 2002 Dec; 33(12):1193-9. PubMed ID: 12514788
[TBL] [Abstract][Full Text] [Related]
11. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
12. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
13. Measurement of crosslinked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D dimer using EIA and latex test.
Hafter R; Schröck R; von Hugo R; Graeff H
Scand J Clin Lab Invest Suppl; 1985; 178():137-44. PubMed ID: 3867114
[TBL] [Abstract][Full Text] [Related]
14. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H
Blood; 1990 Apr; 75(8):1673-8. PubMed ID: 2139349
[TBL] [Abstract][Full Text] [Related]
15. [Ferritin levels of ascites and the contents of cystic ovarian tumors--possibilities of ferritin production and secretion by malignant tumor cells].
Okamoto M; Fukasawa H; Hirata F; Hoshi S
Gan To Kagaku Ryoho; 1984 Feb; 11(2):240-6. PubMed ID: 6696460
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activation in healing human wounds.
Schäfer BM; Maier K; Eickhoff U; Todd RF; Kramer MD
Am J Pathol; 1994 Jun; 144(6):1269-80. PubMed ID: 8203466
[TBL] [Abstract][Full Text] [Related]
17. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity.
Nagy JA; Meyers MS; Masse EM; Herzberg KT; Dvorak HF
Cancer Res; 1995 Jan; 55(2):369-75. PubMed ID: 7812970
[TBL] [Abstract][Full Text] [Related]
19. Role of fibronectin in diagnosis of malignant ascites.
Sood A; Moudgil A; Sood N; Kharay AS; Kaushal S; Narang AP
J Assoc Physicians India; 1997 Apr; 45(4):283-5. PubMed ID: 12521085
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1.
Grunt TW; Oeller H; Somay C; Dittrich E; Fazeny B; Mannhalter C; Dittrich C
J Cell Physiol; 1993 Aug; 156(2):358-66. PubMed ID: 8344991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
